key: cord-0842775-9x7rvscn
authors: Keswani, Anjeni; Dhana, Klodian; Rosenthal, Jamie A.; Moore, Donyea; Mahdavinia, Mahboobeh
title: Atopy is predictive of a decreased need for hospitalization for COVID-19
date: 2020-07-18
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2020.07.012
sha: 9273858553479770cadaaa92236e30a540a03712
doc_id: 842775
cord_uid: 9x7rvscn

nan

The COVID-19 pandemic has caused high utilization of healthcare resources including 1 hospitalization and intensive care unit treatment. There has been considerable interest in 2 determining which clinical factors stratify patients into high or low risk for severe COVID-19 3 illness to aid with clinical decision making. Advanced age, cardiovascular disease and diabetes 4 have been associated with increased COVID-19 severity 1 . Asthma appears to be under-5

represented as a COVID-19 comorbidity compared to its global prevalence of disease 1,2 . To 6 date, the effect of atopic conditions on the disease course of COVID-19 has yet to be fully 7 elucidated. This study is a large, two site cohort of COVID-19 positive patients designed to 8 understand the association between atopic conditions and COVID-19 disease severity. 9

The study was approved by the Institutional Review Board of both participating universities. An 11 electronic medical records (EMR) database search was performed to identify patients tested for 12 COVID-19. All encounters of these patients were carefully reviewed and only cases who were 13 active patients at the health systems, with a detailed medical history available prior to the 14 diagnosis of COVID-19, were included in the study. Through extensive chart review, 15 demographic and clinical factors related to allergy evaluations including active or historical 16 diagnoses of asthma, allergic rhinitis (AR), eczema, and food allergy, and variables related to 17 COVID-19 infection severity were retrieved from the EMR. To confirm these allergy-related 18 variables, charts were initially reviewed by trained researchers for ICD-10 codes and the 19 diagnoses were subsequently verified by clinical history and evidence of allergic sensitization 20 via skin prick or serum IgE testing by board-certified allergists. 21

Logistic regressions were used to compare COVID-19 related outcomes in association with pre-23 existing AR, asthma, eczema and food allergy while adjusting for age, gender, body mass index 24 and race. Patients with a history of AR and/or eczema and/or food allergy were labeled as 25 atopic. Similar regression analysis was performed to compare atopic and non-atopic individuals. 26

Asthmatics were first analyzed as a single group compared to non-asthmatics. Next, asthmatics 27

were divided into allergic asthma, defined as patients with a diagnosis of both AR and asthma, 28 and non-allergic asthma for subgroup analysis. results. Complete data on demographic variables, confirmed allergy diagnoses, and COVID-19 32 management variables was available for 1043 patients who were used for our analysis. 970 33 patients were excluded as they were not active patients in the medical center's EMR prior to 34 their COVID-19 diagnosis. The mean (standard deviation) of age was 50.16 (16.77) years, 43.3% 35 were male and 58.1% were African Americans. There was no significant difference in 36 demographics between the atopic and non-atopic groups. Among these 1043 cases, 257 37 (24.6%) were atopic. Atopy was associated with significantly lower odds of hospitalization for 38 COVID-19 (Table 1) ; 27.6% of atopic and 37.8% of non-atopic COVID-19 patients were 39 hospitalized (adjusted p=0.004). Furthermore, atopy was associated with a decreased duration 40 of hospitalization for COVID-19. When analyzing AR, eczema and food allergy separately, both 41 3 8.1 days in asthmatics vs. non-asthmatics (adjusted p=0.016). When asthmatics were grouped 45 into allergic and non-allergic, only non-allergic asthma was associated with prolonged 46 intubation time (Table 1) . There was no difference in mortality between the atopic and non-47 atopic groups. Treatment regimens for COVID-19 were not notably different between the 48 atopic and non-atopic groups, with minimal use of systemic corticosteroids in this cohort. 49 50 In our series, AR and eczema were associated with a lower rate of hospitalizations, and AR was 51 associated with a lower duration of hospitalization and intubation for COVID-19 infections. This 52 adds greater credence to an earlier report from China in which respiratory allergies were not 53 identified as risk factors for severe COVID-19 illness 1 . In a recent study, Jackson et al. 54 demonstrated that expression of angiotensin-converting enzyme 2 (ACE2), the cell receptor 55 utilized by SARS-CoV-2 for cell entry, was decreased in atopic individuals 3 . Interestingly, 56 reductions in ACE2 expression levels correlate with allergic sensitization, higher levels of total 57

IgE and Type 2 inflammatory (Th-2) cytokines [3] [4] [5] . Interleukin (IL)-13, a major Th-2 cytokine, is 58 shown to significantly reduce ACE2 expression in airway epithelial cells 5 . Our findings of the 59 association of allergic rhinitis and eczema with decreased need of hospitalization for COVID-19 60 provides robust clinical data to support these mechanistic findings. 61

The role of asthma and its association with COVID-19 severity is more complicated 6, 7 . Asthma 63 was not reported in previously published cohorts of COVID-19 from China 1,2 ; while data from 64 the Centers for Disease Control indicates that asthma is present in as high as 27% of 4 explained by the lower rates of asthma in China (2-4%) compared to the United States (8-67 11%) 8, 9 . In the current report, allergic asthma was not associated with any COVID-19 outcome 68 variable despite allergic rhinitis being protective against hospitalization. Furthermore, non-69 allergic asthma was associated with a prolonged intubation time which confirms an earlier 70 study 10 . It is possible that asthma, as a chronic pulmonary disease prone to viral-induced 71 exacerbations, places those with more severe COVID-19 illness at risk for more prolonged lung 72 involvement. However, a co-existing atopic background may mitigate the severe inflammatory 73 response syndrome of COVID-19 in allergic asthmatics, leading to the absence of the prolonged 74 intubation time seen in non-allergic asthmatics. 75

The knowledge that atopy is associated with less severe COVID-19 outcomes can be instructive 77 in clinical risk stratification. Further studies are needed to understand the underlying 78 mechanism of these apparent protective physiologic factors which may prove advantageous in 79 future prevention and treatment strategies.

£= Atopy is defined as presence of allergic rhinitis and/or eczema and/or food allergy.

€= Allergic asthma is defined by asthma diagnosed based on GINA guidelines and evidence of inhalant allergen sensitization and non-allergic asthma are asthmatics without inhalant allergen sensitization. In this paper. those with comorbid asthma and allergic rhinitis are considered allergic asthma and asthmatics without allergic rhinitis are grouped in non-allergic asthma. ¥= P.values for categorical variables are calculated by logistic regression comparing categorical variables adjusted for age, race, sex and body mass index (BMI) , or analysis of covariance (ANCOVA) comparing the adjusted means of continuous variables adjusting for age, race, sex and BMI. Odds ratio (95%confice interval) are reported for categorical variables and beta is reported for continuous variables. 

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma-implications for COVID-19

Type 2 Inflammation Modulates ACE2 and TMPRSS2 in Airway Epithelial Cells

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease

Clinical course of asthma in 4 cases of coronavirus disease 2019 infection

Prevalence, risk factors, and management of asthma in China: a national cross-sectional study

Asthma prolongs intubation in COVID-19